Navigation Links
PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine
Date:7/12/2011

OXFORD, England, July 12, 2011 /PRNewswire/ --


 

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection.  The engagement will utilise PharmaVentures' global transactional expertise in the healthcare and investment business sectors.

Dr Fintan Walton, CEO, PharmaVentures, commented, "We are delighted to have been chosen by Avexa to assist in achieving its business goal of maximising the return on investment in its development compound apricitabine (ATC).  With 20 years' experience of deals and alliances, PharmaVentures can provide Avexa with immediate access to extensive licensing expertise and a network of key decision makers in relevant companies."

Iain Kirkwood, Chairman of Avexa, said, "The appointment of PharmaVentures to work with and complement our management team is the next logical step in the commercialisation of ATC following our successful regulatory meeting with the FDA earlier this year. PharmaVentures have an excellent reputation and track record in this area."

ATC is a novel nucleoside, a class of compound known to be a vital component of anti-HIV therapy.  ATC offers a new extension to existing therapies in the treatment of drug-resistant HIV, especially for those patients with limited remaining therapeutic options.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals.  The licensing team has an established track record in generating outstanding value for PharmaVentures' clients and has assisted in over 100 transactions in the past 20 years.  

About PharmaVentures Limited

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. It also produces the highly popular PharmaDeals® (http://www.pharmadeals.net) range of intelligence products including databases, deals analysis and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).  Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

About Avexa Limited

Avexa Limited (http://www.avexa.com.au) is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

For enquiries regarding this licensing opportunity or how we can help your company to achieve its business goals, please contact:

Kevin Bottomley
Head of Transactions
PharmaVentures Ltd.
kevin.bottomley@pharmaventures.com
+44-7931-144097



'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaVentures Appoints Paul Phull as Senior Director
2. NeoStem to Launch New Service and Has Engaged Healthcare Personality Dr. Manny Alvarez to Serve as Spokesperson
3. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
4. Medical Messenger Partners With ComputerAssistant.com to Provide Key Elements of Meaningful Use Success
5. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
6. Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016
7. Pharmacy Technicians Assist Pharmacy Teams in Development of Drug Shortage Protocols
8. Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management
9. Lilly USA, LLC Launches TruAssist for Patients
10. Swedish Robotic-Assisted Surgical Program Grows, Continues to Gain Momentum
11. Free Statewide Rx Assistance Program Launching in Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):